Quick Answer
RenovoRx, Inc. reported Cash and Equivalents of $7.02 million for fiscal year 2025.
RenovoRx, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.02M | -1.8% |
| 2024 | $7.15M | +509.9% |
| 2023 | $1.17M | -73.3% |
| 2022 | $4.39M | -71.1% |
| 2021 | $15.19M | +746.4% |
| 2020 | $1.79M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.04M | +5.0% | -18.4% |
| June 30, 2025 | $12.31M | +4.9% | -15.6% |
| March 31, 2025 | $14.58M | +232.2% | +103.8% |
| December 31, 2024 | $7.15M | +509.9% | -25.2% |
| September 30, 2024 | $9.56M | +196.4% | -18.6% |
| June 30, 2024 | $11.74M | +97.2% | +167.5% |
| March 31, 2024 | $4.39M | +17.9% | +274.2% |
| December 31, 2023 | $1.17M | -73.3% | -63.6% |
- RenovoRx, Inc. showed a decrease of -1.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, RenovoRx, Inc.’s cash and equivalents has grown by 291.3% (from $1.79 million to $7.02 million).
- The most recent figure is from RenovoRx, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: